MYC and breast cancer: Previous studies have shown that BET degraders inhibited c-Myc in breast cancer and prostate cancer cells, and that p53 was involved in the anticancer activity mediated by BET inhibitor JQ1 in acute myeloid leukemia and medulloblastoma cells17,18.